GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS (IST:GENIL) » Definitions » Risk Assessment

Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Risk Assessment


View and export this data going back to 2021. Start your Free Trial

What is Gen Ilac Veglik Urunlerinayi ve Ticaret AS Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Gen Ilac Veglik Urunlerinayi ve Ticaret AS is: Moderate Risk: Sensitive, better choose undervalued stock.


Competitive Comparison of Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Risk Assessment falls into.



Gen Ilac Veglik Urunlerinayi ve Ticaret AS  (IST:GENIL) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS Risk Assessment Related Terms

Thank you for viewing the detailed overview of Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Business Description

Traded in Other Exchanges
N/A
Address
Mustafa Kemal Mahallesi 2119.Sk. No:3, Cankaya, Ankara, TUR, 06520
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.

Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Headlines

No Headlines